Clinical and economic impact of ibalizumab for people with multidrug-resistant HIV in the United States

BACKGROUND: We projected the clinical outcomes, cost-effectiveness, and budget impact of ibalizumab plus an optimized background regimen (OBR) for people with multidrug-resistant HIV in the US. METHODS: Using the Cost-Effectiveness of Preventing AIDS Complications (CEPAC) microsimulation model and a...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Acquir Immune Defic Syndr
Egile Nagusiak: MILLHAM, Lucia R.I., SCOTT, Justine A., SAX, Paul E., SHEBL, Fatma M., REDDY, Krishna P., LOSINA, Elena, WALENSKY, Rochelle P., FREEDBERG, Kenneth A.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2020
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7066538/
https://ncbi.nlm.nih.gov/pubmed/31929403
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/QAI.0000000000002241
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak